Treatment References

1. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 59(1):56-66, 2009.
2. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 347(16):1233-41, 2002.
3. Darby S, McGale P, Correa C, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 378(9804):1707-16, 2011.
4. National Cancer Institute. Lymphedema – patient version. http://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-pdq, 2019.
5. Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 265(3):581-589, 2017.
6. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer V.1.2019. http://www.nccn.org/, 2019.
7. Smith GL, Xu Y, Shih YC, et al. Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg. 209(4):425-433.e2, 2009.
8. Lautner M, Lin H, Shen Y, et al. Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg. 150(8):778-86, 2015.
9. Patrick JL, Hasse ME, Feinglass J, Khan SA. Trends in adherence to NCCN guidelines for breast conserving therapy in women with Stage I and II breast cancer: Analysis of the 1998-2008 National Cancer Data Base. Surg Oncol. 26(4):359-367, 2017.
10. National Cancer Institute. Radiation therapy and you: support for people with cancer. https://www.cancer.gov/publications/patient-education/radiationttherapy.pdf, 2016.
11. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 14(6):500-15, 2013.
12. Taylor C, Correa C, Duane FK, et al. for the Early Breast Cancer Trialists’ Collaborative Group. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 35(15):1641-1649, 2017.
13. Kirova YM, De Rycke Y, Gambotti L, Pierga J-Y, Asselain B, Fourquet A for the Institut Curie Breast Cancer Study Group. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 98(5):870-4, 2008.
14. Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 115(18):4055-63, 2009.
15. Strnad V, Ott OJ, Hildebrandt G, et al. for the Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet. 387(10015):229-38, 2016.
16. White J, Winter K, Kuske RR, et al. Long-term cancer outcomes from Study NRG Oncology/RTOG 9517: a phase 2 study of accelerated partial breast irradiation with multicatheter brachytherapy after lumpectomy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 95(5):1460-1465, 2016.
17. Shah C, Badiyan S, Ben Wilkinson J, et al. Treatment efficacy with accelerated partial breast irradiation (APBI): final analysis of the American Society of Breast Surgeons MammoSite(®) breast brachytherapy registry trial. Ann Surg Oncol. 20(10):3279-85, 2013.
18. Ajkay N, Collett AE, Bloomquist EV, Gracely EJ, Frazier TG, Barrio AV. A comparison of complication rates in early-stage breast cancer patients treated with brachytherapy versus whole-breast irradiation. Ann Surg Oncol. 22(4):1140-5, 2015.
19. Coles CE, Griffin CL, Kirby AM, et al. for the IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 390(10099):1048-1060, 2017.
20. Schäfer R, Strnad V, Polgár C, et al. for the Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol. 19(6):834-844, 2018.
21. Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 31(32):4038-45, 2013.
22. Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol. 7(2):73-79, 2017.
23. Vaidya JS, Wenz F, Bulsara M, et al. on behalf of the TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 383(9917):603-13, 2014.
24. Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW. Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist. 18(7):885-91, 2013.
25. Rugo HS, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 317(6):606-614, 2017.
26. Nangia J, Wang T, Osborne C, et al. Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA. 317(6):596-605, 2017.
27. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press, 2017.
28. American Cancer Society. Diarrhea. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/stool-or-urine-changes/diarrhea.html, 2015.
29. Krishnamurthi SS and Macaron C. Management of acute chemotherapy-related diarrhea. In: UpToDate (Drews RE and Savarese DMF, eds.). Waltham, MA: UpToDate, 2018.
30. Markes MH. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 9:CD005001, 2016.
31. Mustian KM, Alfano CM, Heckler C, et al. Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol. 3(7):961-968, 2017.
32. Escalante CP. Cancer-related fatigue: treatment. In: UpToDate (Hesketh PJ, Ganz PA, Vora SR, eds.). Waltham, MA: UpToDate, 2018.
33. National Cancer Institute. Chemotherapy and you: support for people with cancer. http://www.cancer.gov/publications/patient-education/chemotherapy-and-you.pdf, 2018.
34. Ruddy KJ and Ginsburg ES. Chapter 90: Reproductive issues in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
35. American College of Obstetricians and Gynecologists' Committee on Gynecologic Practice: Committee Opinion No. 584: oocyte cryopreservation. Obstet Gynecol. 123(1):221-2, 2014.
36. Stan D, Hershman D, Loprinzi CL. Chapter 51: Management of menopausal symptoms in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
37. Saquib N, Flatt SW, Natarajan L, et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women's healthy eating and living (WHEL) study. Breast Cancer Res Treat. 105(2):177-86, 2007.
38. Manneville F, Rotonda C, Conroy T, Bonnetain F, Guillemin F, Omorou AY. The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer. Cancer. 124(4):797-806, 2018.
39. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 123(3):627-35, 2010.
40. Ewertz M, Jensen MB, Gunnarsdóttir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 29(1):25-31, 2011.
41. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat. 134(2):769-81, 2012.
42. Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer. 15:865, 2015.
43. Goedendorp MM, Andrykowski MA, Donovan KA, et al. Prolonged impact of chemotherapy on fatigue in breast cancer survivors: A longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer. 118(15):3833-41, 2012.
44. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 30(29):3578-87, 2012.
45. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 30(30):3675-86, 2012.
46. Mandelblatt JS, Clapp JD, Luta G, et al. Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer. 122(22): 3555–3563, 2016.
47. Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol. 35(5): 506–514, 2017.
48. Hermelink K, Bühner M, Sckopke P, et al. Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. J Natl Cancer Inst. 109(10):djx057, 2017.
49. Bluethmann SM, Alfano CM, Clapp JD, et al. Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance). Breast Cancer Res Treat. 165(3):677-86, 2017.
50. Mandelblatt JS, Small BJ, Luta G, et al. Cancer-related cognitive outcomes among older breast cancer survivors in the Thinking and Living With Cancer Study. J Clin Oncol. 36(32):3211-3222, 2018.
51. National Cancer Institute. Memory or concentration problems and cancer treatment. https://www.cancer.gov/about-cancer/treatment/side-effects/memory, 2015.
52. Azim HA Jr, de Azambuja E, Colozza M, Bines J, Piccart MJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol. 22(9):1939-47, 2011.
53. Wolff AC, Blackford AL, Visvanathan K, et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: the National Comprehensive Cancer Network experience. J Clin Oncol. 33(4):340-8, 2015.
54. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 32(20):2159-65, 2014.
55. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 34(6):581-7, 2016.
56. Freedman RA, Seisler DK, Foster JC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat. 161(2):363-373, 2017.
57. Rosenstock AS, Niu J, Giordano SH, Zhao H, Wolff AC, Chavez-MacGregor M. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients. Cancer. 124(5):899-906, 2018.
58. Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 376(22):2147-2159, 2017.
59. Majewski IJ, Nuciforo P, Mittempergher L, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. J Clin Oncol. 33(12):1334-9, 2015.
60. Pogue-Geile KL, Song N, Jeong JH, et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol. 33(12):1340-7, 2015.
61. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361(2):123-34, 2009.
62. Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 19(4):497-509, 2018.
63. U.S. Food and Drug Administration. Biosimilar development, review, and approval. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580429.htm, 2017.
64. Mittendorf EA, Peoples GE. Injecting hope-a review of breast cancer vaccines. Oncology (Williston Park). 30(5):475-81, 485, 2016.
65. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 12(4):384-9, 2016.
66. Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 35(24):2838-2847, 2017.
67. Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 110(6):560-567, 2018.
68. Sparano J, O'Neill A, Alpaugh K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 4(12):1700-1706, 2018.
69. Trapp E, Janni W, Schindlbeck C, et al. for the SUCCESS Study Group. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst. 111(4):380-387, 2019.
70. Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 15(4):406-14, 2014.
71. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 340:c693, 2010.
72. Regan MM, Leyland-Jones B, Bouzyk M, et al. on behalf of the Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst. 104(6):441-451, 2012.
73. Rae JM, Drury S, Hayes DF, et al. on behalf of the ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 104(6):452-460, 2012.
74. Davies C, Godwin J, Gray R, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 378(9793):771-84, 2011.
75. Dowsett M, Forbes JF, Bradley R, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 386(10001):1341-52, 2015.
76. Francis PA, Pagani O, Fleming GF, et al. for the SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 379(2):122-137, 2018.
77. Murphy B and Muss HB. Hormonal therapy of breast cancer: state of the art. Oncology (Huntingt). 11: 7-13, 1997.
78. Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat. 136(2):495-502, 2012.
79. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 108(7):1515-24, 2013.
80. Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 34(21):2452-9, 2016.
81. Davies C, Pan H, Godwin J, et al. for the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 381(9869):805-16, 2013.
82. Vogel VG, Costantino JP, Wickerham DL, et al. for the National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res. 3(6):696-706, 2010.
83. Rimawi MF and Osborne CK. Chapter 43: Adjuvant systemic therapy: endocrine therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
84. Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol. 24(6):1434-43, 2013.
85. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. for the BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 361(8):766-76, 2009.
86. Cuzick J, Sestak I, Baum M, et al. for the ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11(12):1135-41, 2010.
87. Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 30(7):709-17, 2012.
88. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 37(5):423-438, 2019.
89. Goss PE, Ingle JN, Pritchard KI, et al. Aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 375(3):209-19, 2016.
90. De Placido S, Gallo C, De Laurentiis M, et al. for the GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 19(4):474-485, 2018.
91. Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 110(1): djx141, 2018.
92. Goss PE, Ingle JN, Alés-Martínez JE, et al. for the NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 364(25):2381-91, 2011.
93. Cuzick J, Sestak I, Forbes JF, et al. on behalf of the IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 383(9922):1041-8, 2014.
94. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 126(2):295-310, 2011.
95. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 103(17):1299-309, 2011.
96. Beckwée D, Leysen L, Meuwis K, Adriaenssens N. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 25(5):1673-1686, 2017.
97. Spagnolo F, Sestak I, Howell A, Forbes JF, Cuzick J. Anastrozole-induced carpal tunnel syndrome: results from the International Breast Cancer Intervention Study II Prevention Trial. J Clin Oncol. 34(2):139-43, 2016.
98. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 33(10):1104-11, 2015.
99. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 33(10):1104-11, 2015.
100. Baglia ML, Lin IH, Cartmel B, et al. Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors. Cancer. 2019 Mar 6 [Epub ahead of print].
101. Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 120(1):127-34, 2010.
102. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28(35):5132-9, 2010.
103. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 19(3):420-32, 2008.
104. Rathbone EJ, Brown JE, Marshall HC, et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol. 31(21):2685-91, 2013.
105. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 19(8):1407-16, 2008.
106. Harris SR, Schmitz KH, Campbell KL, McNeely ML. Clinical practice guidelines for breast cancer rehabilitation: syntheses of guideline recommendations and qualitative appraisals. Cancer. 118(8 Suppl):2312-24, 2012.
107. Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 32(35):3948-58, 2014.
108. Ribi K, Luo W, Bernhard J, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 34(14):1601-10, 2016.
109. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical practice guideline update on ovarian suppression. J Clin Oncol. 34(14):1689-701, 2016.
110. Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. (4):CD004562, 2008.
111. Rakha EA, Pinder SE, Bartlett JM, et al. for the National Coordinating Committee for Breast Pathology. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 68(2):93-9, 2015.
112. Esserman LJ and Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. In: UpToDate. Hayes DF, Burstein H, Vora SR (eds.). Waltham, MA: UpToDate, 2018.
113. Gianni L, Dafni U, Gelber RD, et al. for the Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12(3):236-244, 2011.
114. Slamon D, Eiermann W, Robert N, et al. for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365(14):1273-83, 2011.
115. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 32(33):3744-52, 2014.
116. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac safety analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. J Clin Oncol. 34(6):581-7, 2016.
117. von Minckwitz G, Huang CS, Mano MS, et al. for the KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 380(7):617-628, 2019.
118. U.S. Food and Drug Administration (FDA). Kadcyla labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf, 2019.
119. von Minckwitz G, Procter M, de Azambuja E, et al. for the APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 377(2):122-131, 2017.
120. U.S. Food and Drug Administration (FDA). FDA grants regular approval to pertuzumab for adjuvant treatment of HER2-positive breast cancer. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm590005.htm, 2017.
121. Martin M, Holmes FA, Ejlertsen B, et al. for the ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18(12):1688-1700, 2017.
122. U.S. Food and Drug Administration (FDA). FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm567259.htm, 2017.
123. Chen Y, Shi XE, Tian JH, Yang XJ, Wang YF, Yang KH. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis. Medicine (Baltimore). 97(20):e10634, 2018.
124. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 30(32):3960-6, 2012.
125. Li XB, Krishnamurti U, Bhattarai S, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 145(6):871-8, 2016.
126. Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 35(18):2062-2081, 2017.
127. Paterson AH1, Anderson SJ, Lembersky BC, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 13(7):734-42, 2012.
128. Coleman R, Powles T, Paterson A, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 386(10001):1353-61, 2015.
129. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER Cancer Statistics Review, 1975-2015. Table 4.13. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2015/, accessed February 8, 2019.
130. Carlson RW. Chapter 67: Surveillance of patients following primary therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
131. Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group trials I to V. J Clin Oncol. 34(9):927-35, 2016.
132. Harris JR and Morrow M. Chapter 35: Breast-conserving surgery, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
133. Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol. 29(29):3885-91, 2011.
134. Braunstein LZ, Taghian AG, Niemierko A, et al. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Res Treat. 161(1):173-179, 2017.
135. Overmoyer B and Pierce LJ. Chapter 59: Inflammatory Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
136. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 55(5):1200-8, 2003.
137. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27(18):2938-45, 2009.
138. Yang R, Cheung MC, Hurley J, et al. A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat. 117(3):631-41, 2009.
139. Tsai CJ, Li J, Gonzalez-Angulo AM, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. 38(3):242-7, 2015.
140. Mehrara BJ and Ho AY. Chapter 36: Breast reconstruction, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
141. Fischer JP, Nelson JA, Kovach SJ, Serletti JM, Wu LC, Kanchwala S. Impact of obesity on outcomes in breast reconstruction: analysis of 15,937 patients from the ACS-NSQIP datasets. J Am Coll Surg. 217(4):656-64, 2013.
142. Matsen CB, Mehrara B, Eaton A, et al. Skin flap necrosis after mastectomy with reconstruction: a prospective study. Ann Surg Oncol. 23(1):257-64, 2016.
143. Panayi AC, Agha RA, Sieber BA, Orgill DP. Impact of obesity on outcomes in breast reconstruction: a systematic review and meta-analysis. J Reconstr Microsurg. 34(5):363-375, 2018.
144. Zhong T, Hu J, Bagher S, et al. Decision regret following breast reconstruction: the role of self-efficacy and satisfaction with information in the preoperative period. Plast Reconstr Surg. 132(5):724e-734e, 2013.
145. Lee GK, Sheckter CC. Breast reconstruction following breast cancer treatment-2018. JAMA. 320(12):1277-1278, 2018.
146. Bennett KG, Qi J, Kim HM, Hamill JB, Pusic AL, Wilkins EG. Comparison of 2-year complication rates among common techniques for postmastectomy breast reconstruction. JAMA Surg. 153(10):901-908, 2018.
147. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med. 342(11):781-90, 2000.
148. Singh N1, Picha GJ, Hardas B, Schumacher A, Murphy DK. Five-year safety data for more than 55,000 subjects following breast implantation: comparison of rare adverse event rates with silicone implants versus national norms and saline implants. Plast Reconstr Surg. 140(4):666-679, 2017.
149. U.S. Food and Drug Administration. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239995.htm, 2019.
150. Gidengil CA, Predmore Z, Mattke S, van Busum K, Kim B. Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg. 135(3):713-20, 2015.
151. Leberfinger AN, Behar BJ, Williams NC, et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 152(12):1161-1168, 2017.
152. de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 4(3):335-341, 2018.
153. Colwell AS, Christensen JM. Nipple-sparing mastectomy and direct-to-implant breast reconstruction. Plast Reconstr Surg. 140(5S Advances in Breast Reconstruction):44S-50S, 2017.
154. Dikmans RE, Negenborn VL, Bouman MB, et al. Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial. Lancet Oncol. 18(2):251-258, 2017.
155. Jones G, Yoo A, King V, et al. Prepectoral immediate direct-to-implant breast reconstruction with anterior AlloDerm coverage. Plast Reconstr Surg. 140(6S Prepectoral Breast Reconstruction):31S-38S, 2017.
156. U.S. Food and Drug Administration (FDA). Risks of breast implants. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm064106.htm, 2018.
157. Ricci JA, Epstein S, Momoh AO, Lin SJ, Singhal D, Lee BT. A meta-analysis of implant-based breast reconstruction and timing of adjuvant radiation therapy. J Surg Res. 218:108-116, 2018
158. Sarik JR, Bank J, Wu LC, Serletti JM. Superficial inferior epigastric artery: learning curve versus reality. Plast Reconstr Surg. 137(1):1e-6e, 2016.
159. LoTempio MM, Allen RJ. Breast reconstruction with SGAP and IGAP flaps. Plast Reconstr Surg. 126(2):393-401, 2010.
160. Mirzabeigi MN, Au A, Jandali S, Natoli N, Sbitany H, Serletti JM. Trials and tribulations with the inferior gluteal artery perforator flap in autologous breast reconstruction. Plast Reconstr Surg. 128(6):614e-24e, 2011.
161. Yi M, Kronowitz SJ, Meric-Bernstam F, et al. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 117(5):916-24, 2011.
162. Romics L Jr, Chew BK, Weiler-Mithoff E, et al. Ten-year follow-up of skin-sparing mastectomy followed by immediate breast reconstruction. Br J Surg. 99(6):799-806, 2012.
163. Mota BS, Riera R, Ricci MD, et al. Nipple- and areola-sparing mastectomy for the treatment of breast cancer. Cochrane Database Syst Rev. 11:CD008932, 2016.
164. Tang R, Coopey SB, Merrill AL, et al. Positive nipple margins in nipple-sparing mastectomies: rates, management, and oncologic safety. J Am Coll Surg. 222(6):1149-55, 2016.
165. Smith BL, Tang R, Rai U, et al. Oncologic safety of nipple-sparing mastectomy in women with breast cancer. J Am Coll Surg. 225(3):361-365, 2017.
166. Jakub JW, Peled AW, Gray RJ, et al. Oncologic safety of prophylactic nipple-sparing mastectomy in a population with BRCA mutations: a multi-institutional study. JAMA Surg. 153(2):123-129, 2018.
167. American Cancer Society. What to expect after breast reconstruction surgery. https://www.cancer.org/cancer/breast-cancer/reconstruction-surgery/what-to-expect-after-breast-reconstruction-surgery.html, 2017.
168. U.S. Department of Labor. Your rights after a mastectomy. https://www.dol.gov/sites/default/files/ebsa/about-ebsa/our-activities/resource-center/publications/your-rights-after-a-mastectomy.pdf, 2018.
169. Schnipper LE, Smith TJ, Raghavan D, et al. American society of clinical oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 30(14):1715-24, 2012.
170. National Cancer Institute. General information about breast cancer and pregnancy. http://www.cancer.gov/types/breast/patient/pregnancy-breast-treatment-pdq, 2017.
171. Litton JK and Theriault RL. Chapter 65: Breast cancer during pregnancy and subsequent pregnancy in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
172. Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 1(8):1145-53, 2015.
173. Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 31(20):2532-9, 2013.
174. Johansson ALV, Andersson TM, Hsieh CC, et al. Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. Int J Cancer. 142(7):1343-1354, 2018.
175. American Cancer Society. Breast Cancer Facts and Figures 2017-2018. Atlanta, GA: American Cancer Society, 2017.
176. Partridge AH, Goldhirsch A, Gelber S, Gelber RD. Chapter 85: Breast Cancer in Younger Women, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition, Lippincott Williams & Wilkins, 2014.
177. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 43(11):1646-53, 2007.
178. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 360(9):902-11, 2009.
179. Moore HC, Unger JM, Phillips KA, et al. for the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 372(10):923-32, 2015.
180. Lambertini M, Boni L, Michelotti A, et al. for the GIM Study Group. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 314(24):2632-40, 2015.
181. Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2(1):65-73, 2016.
182. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER Cancer Statistics Review, 1975-2016. Table 1.16: Lifetime risk (percent) of being diagnosed with cancer by site and race/ethnicity females, 21 SEER areas, 2014-2016. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2016/, accessed May 8, 2019.
183. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER Cancer Statistics Review, 1975-2015. Table 1.15: Lifetime risk (percent) of being diagnosed with cancer by site and race/ethnicity males, 21 SEER areas, 2014-2016. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2016/, accessed May 8, 2019.
184. American Cancer Society. Cancer Facts and Figures 2017. Atlanta, GA: American Cancer Society, 2017.
185. American Cancer Society. Cancer Facts and Figures 2019. Atlanta, GA: American Cancer Society, 2019.
186. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 28(2):232-9, 2010.
187. Jain S and Gradishar WJ. Chapter 61: Male breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
188. National Cancer Institute. Male breast cancer treatment. http://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq, 2018.
189. American Cancer Society. Can breast cancer in men be found early? https://www.cancer.org/cancer/breast-cancer-in-men/detection-diagnosis-staging/detection.html, 2018.
190. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER*Explorer. Recent trends in SEER incidence rates, 2000-2016, by sex. National Cancer Institute. Bethesda, MD. Accessed on May 8, 2019. https://seer.cancer.gov/explorer/, 2019.
191. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Genetic/familial high-risk assessment: breast and ovarian V.3.2019. http://www.nccn.org/, 2019.
192. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 367(9510):595-604, 2006.
193. Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol. 35(20):2240-2250, 2017.
194. National Cancer Institute. Genetics of breast and gynecologic cancers: High-penetrance breast and/or gynecologic cancer susceptibility genes. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq#link/_113_toc, 2019.
195. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 353(5):487-97, 2005.
196. American Cancer Society. What are the phases of clinical trials? https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html, 2017.
197. Cancer Research UK. Phases of clinical trials. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/phases-of-clinical-trials#phase0, 2015.
198. Murgo AJ, Kummar S, Rubinstein L, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res. 14(12):3675-82, 2008.
199. National Cancer Institute. Questions to ask your doctor about treatment clinical trials. http://www.cancer.gov/about-cancer/treatment/clinical-trials/questions, 2016.
200. Reich M, Lesur A, Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat. 110(1):9-17, 2008.
201. Schreiber JA, Brockopp DY. Twenty-five years later--what do we know about religion/spirituality and psychological well-being among breast cancer survivors? A systematic review. J Cancer Surviv. 6(1):82-94, 2012.
202. Cherny NI and Truong PT. Chapter 79: Brachial plexopathy in patients with breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
203. Vilholm OJ, Cold S, Rasmussen L, Sindrup SH. The postmastectomy pain syndrome: an epidemiological study on the prevalence of chronic pain after surgery for breast cancer. Br J Cancer. 99:604-610, 2008.
204. Gärtner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 302(18):1985-92, 2009.
205. Schmitz KH, Speck RM, Rye SA, DiSipio T, Hayes SC. Prevalence of breast cancer treatment sequelae over 6 years of follow-up: the Pulling Through Study. Cancer. 118(8 Suppl):2217-25, 2012.
206. Kraus-Tiefenbacher U, Sfintizky A, Welzel G, et al. Factors of influence on acute skin toxicity of breast cancer patients treated with standard external beam radiotherapy (EBRT) after breast conserving surgery (BCS). Radiat Oncol. 7(1):217, 2012.
207. American Cancer Society. Developing a pain control plan. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/pain/developing-a-pain-control-plan.html, 2019.
208. National Cancer Institute. Pain control: Support for people with cancer. http://www.cancer.gov/publications/patient-education/paincontrol.pdf, 2019.
209. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Adult cancer pain V.1.2019. http://www.nccn.org/, 2019.
210. Goedendorp MM, Andrykowski MA, Donovan KA, et al. Prolonged impact of chemotherapy on fatigue in breast cancer survivors: A longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer. 118(15):3833-41, 2012.
211. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ. 344:e70, 2012.
212. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 11:CD006145, 2012.
213. Hayes SC, Rye S, Disipio T, et al. Exercise for health: a randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. Breast Cancer Res Treat. 137(1):175-86, 2013.
214. Bower JE, Garet D, Sternlieb B, et al. Yoga for persistent fatigue in breast cancer survivors: a randomized controlled trial. Cancer. 118(15):3766-75, 2012.
215. Cramer H, Lauche R, Klose P, Lange S, Langhorst J, Dobos GJ. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev. 1:CD010802, 2017.
216. Molassiotis A, Bardy J, Finnegan-John J, et al. Acupuncture for cancer-related fatigue in patients with breast cancer: a pragmatic randomized controlled trial. J Clin Oncol. 30(36):4470-6, 2012.
217. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol. 30(30):3687-96, 2012.
218. Montgomery GH, David D, Kangas M, et al. Randomized controlled trial of a cognitive-behavioral therapy plus hypnosis intervention to control fatigue in patients undergoing radiotherapy for breast cancer. J Clin Oncol. 32(6):557-63, 2014.
219. Lengacher CA, Reich RR, Paterson CL, et al. Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 34(24):2827-34, 2016.
220. Abrahams HJG, Gielissen MFM, Donders RRT, et al. The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial. Cancer. 123(19):3825-3834, 2017.
221. Escalante CP. Cancer-related fatigue: treatment, in Up-to-Date (Hesketh PJ, Ganz PA and Vora SR, editors.). Up-to-Date, 2018.
222. Mustian KM, Sprod LK, Janelsins M, et al. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol. 31(26): 3233-41, 2013.
223. Lengacher CA, Reich RR, Paterson CL, et al. The effects of mindfulness-based stress reduction on objective and subjective sleep parameters in women with breast cancer: a randomized controlled trial. Psychooncology. 24(4):424-32, 2015.
224. Garland SN, Carlson LE, Stephens AJ, Antle MC, Samuels C, Campbell TS. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol. 32(5):449-57, 2014.
225. Roscoe JA, Garland SN, Heckler CE, et al. Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. J Clin Oncol. 33(2):165-71, 2015.
226. Irwin MR, Olmstead R, Carrillo C, et al. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol. 35(23):2656-2665, 2017.
227. Zachariae R, Amidi A, Damholdt MF, et al. Internet-delivered cognitive-behavioral therapy for insomnia in breast cancer survivors: a randomized controlled trial. J Natl Cancer Inst. 110(8):880-887, 2018.
228. Lu W, Cui Y, Chen X, et al. Changes in quality of life among breast cancer patients three years post-diagnosis. Breast Cancer Res Treat. 114(2):357-69, 2009.
229. Shapiro SL, Lopez AM, Schwartz GE, et al. Quality of life and breast cancer: relationship to psychosocial variables. J Clin Psychol. 57(4):501-19, 2001.
230. Horgan O, Holcombe C, Salmon P. Experiencing positive change after a diagnosis of breast cancer: a grounded theory analysis. Psychooncology. 20(10):1116-25, 2011.
231. Perkins EA, Small BJ, Balducci L, Extermann M, Robb C, Haley WE. Individual differences in well-being in older breast cancer survivors. Crit Rev Oncol Hematol. 62(1):74-83, 2007.
232. Gnant M, Pfeiler G, Steger GG, et al. for the Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20(3):339-351, 2019. 
233. American Cancer Society. Breast Cancer Facts and Figures 2019-2020. Atlanta, GA: American Cancer Society, 2019.
234. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER*Explorer. 5-year SEER relative survival rates, by sex and stage at diagnosis, 2009-2015. National Cancer Institute. Bethesda, MD. Accessed on November 14, 2019. https://seer.cancer.gov/explorer/, 2019.
235. U.S. Food and Drug Administration. Biosimilar and interchangeable products. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm, 2017.
236. Saura C, Hlauschek D, Oliveira M, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 20(9):1226-1238, 2019.
237. Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2019 Dec 11 [Epub ahead of print].
238. Coleman R, Finkelstein DM, Barrios C, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Dec 2 [Epub ahead of print].
239. American Cancer Society. Cancer Facts and Figures 2020. Atlanta, GA: American Cancer Society, 2020.

Updated 01/23/20